Product Details
| Product Name:
ZCL278 |
CAS No.:
587841-73-4 |
| Purity:
99.72% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | ZCL278 |
| Description | ZCL278 is a selective Cdc42 GTPase inhibitor. |
| Cell Research | ZCL278 is prepared in DMSO and stored, and then diluted with appropriate medium before use[1]. To determine cell viability, PC-3 cells are incubated for 24 h with or without the Cdc42 activator, ZCL278, or NSC23766. By using the trypan blue dye exclusion method, the numbers of live and dead cells are obtained with a Countess Automated Cell Counter. P values are assigned in each experiment, and any null hypothesis with probability level <95% is rejected[1]. |
| Kinase Assay | Lyophilized Cdc42 protein is reconstituted to 5 mg/mL in a buffer consisting of 50 mM Tris, 0.5 mM MgCl2, 50 mM NaCl, 3% (wt/vol) sucrose, and 0.6% dextran. The stock solution is then diluted to 1 μM in 5 mM phosphate buffer, pH 7.4. Into a quartz cuvettete containing Cdc42 solution, aliquots of ZCL278 are added and incubated for 5 min before each fluorescent measurement. The excitation wavelength is 275 nm, and the fluorescence of tryptophan at 350 nm is measured after each addition. The titration curve is fitted using the equimolar specific binding model in GraphPad, and the Kd is calculated[1]. |
| In vivo | ZCL278 reduces the JUNV RNA load in the spleen by over 33-fold, rendering JUNV RNA undetectable in 5 of 8 mice. These results mirror those observed in Gabapentin-treated mice, demonstrating ZCL278's ability to abrogate JUNV replication [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 40 mg/mL (68.39 mM), Sonication is recommended.
|
| Keywords | organization | Ras | Golgi | prostate | actin-based | cellular | Inhibitor | motility | metastatic | inhibit | Cdc42 | Cdc42-ZCL278 | ZCL-278 | cancer | ZCL278 |
| Inhibitors Related | Ribociclib | Ketoconazole | MRTX1133 | Salirasib | RMC-6236 | CASIN | Palbociclib | Sodium Oxamate | Abemaciclib | Sotorasib | Dinaciclib | Abemaciclib methanesulfonate |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Anti-Cancer Metabolism Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:10083-24-6
$39.00 / 5mg
-
-
CAS:68027-14-5
$389.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$5.00/5KG |
VIP7Y
|
Career Henan Chemical Co
|
2019-09-03 |
United States